ClinicalTrials.gov
ClinicalTrials.gov Menu

Gender Dysphoria Among Adolescents (Norwegian Title: Kjønnsdysfori Blant Ungdom)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03643120
Recruitment Status : Recruiting
First Posted : August 22, 2018
Last Update Posted : August 22, 2018
Sponsor:
Information provided by (Responsible Party):
Reidar Schei Jessen, Oslo University Hospital

Brief Summary:
The aim of this study is to explore how gender dysphoria is experienced among adolescents aged 13 - 18 from a clinical population. The method is qualitative, with a phenomenological approach. Qualitative in-depth data on how gender dysphoria is experienced by the adolescents themselves is lacking in the research literature. As a consequence the within perspective from the clients is lacking. In addition, one aim is to help develop further hypothesis and clinical theory and rationale.

Condition or disease Intervention/treatment Phase
Gender Dysphoria Other: Qualitative interview Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Qualitative interviews, 15 - 20 participants.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Gender Dysphoria Among Adolescents
Actual Study Start Date : August 20, 2018
Estimated Primary Completion Date : May 1, 2019
Estimated Study Completion Date : September 1, 2021

Arm Intervention/treatment
Development of diagnostic typology
One main goal is to Development a typology of sub-types of gender dysphoria.
Other: Qualitative interview
Explorative study of gender dysphoria.




Primary Outcome Measures :
  1. Clinical sub-types [ Time Frame: 2021 ]
    The aim is to develop a typology to describe gender dysphoria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   13 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Referred to the National Treatment Unit for Transsexuality/Gender dysphoria

Exclusion Criteria:

  • Not referred to the National Treatment Unit for Transsexuality/Gender dysphoria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03643120


Contacts
Contact: Reidar Schei Jessen, Master of science 004745222800 reijes@ous-hf.no

Locations
Norway
Oslo university hospital Recruiting
Oslo, Norway, 0424
Contact: Reidar Schei Jessen, Master of science    004745222800    reijes@ous-hf.no   
Contact: Ira Haraldsen, MD    92011533    ira.haraldsen@ouf-hf.no   
Sponsors and Collaborators
Oslo University Hospital

Responsible Party: Reidar Schei Jessen, PhD candidate, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT03643120     History of Changes
Other Study ID Numbers: 2018/1088/REK sør-øst C
First Posted: August 22, 2018    Key Record Dates
Last Update Posted: August 22, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: The interviews will we transcribed. Not yet decided whether the transcribed material will be made available.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Depressive Disorder, Major
Gender Dysphoria
Depressive Disorder
Mood Disorders
Mental Disorders
Sexual Dysfunctions, Psychological